NOLIPREL

Package leaflet: Information for the patient

Warning! Keep this leaflet! Information on the immediate packaging in a foreign language.
Noliprel (Noliprel Arginine), 2.5 mg + 0.625 mg, coated tablets
Perindoprilum argininum + Indapamidum
Noliprel and Noliprel Arginine are different trade names for the same medicine.
Please read the entire leaflet carefully before using the medicine, as it contains
important information for the patient.

• Keep this leaflet so that you can read it again if necessary.
• If you have any doubts, consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not give it to others. The medicine may harm another person, even if their symptoms are the same as yours.
• If you experience any adverse reactions, including any not listed in this leaflet, inform your doctor or pharmacist. See section 4.

Table of contents:

1. What Noliprel is and what it is used for
2. Important information before taking Noliprel
3. How to take Noliprel
4. Possible side effects
5. How to store Noliprel
6. Contents of the pack and other information

1. What Noliprel is and what it is used for

Noliprel is a combination medicine containing two active substances: perindopril and indapamide.
It is an antihypertensive medicine used to treat high blood pressure (hypertension) in adults.
Perindopril belongs to a group of medicines called angiotensin-converting enzyme (ACE) inhibitors. These medicines work by relaxing blood vessels, making it easier for the heart to pump blood.
Indapamide is a diuretic medicine. Diuretics increase the amount of urine produced by the kidneys. Indapamide differs from other diuretics in that it only slightly increases urine output.
Both active substances lower blood pressure and work together to help normalize the patient's blood pressure.

2. Important information before using Noliprel

When not to use Noliprel:

• if the patient is allergic to perindopril or other ACE inhibitors, to indapamide or other sulfonamides, or to any of the other ingredients of this medicine (listed in section 6);
• if the patient previously experienced symptoms such as wheezing, £swelling of the face or tongue, severe itching or intense skin rashes while taking an ACE inhibitor, or if such symptoms occurred in the patient or a blood relative under any other circumstances (a condition called angioedema);
• if the patient has diabetes or kidney function disorders and is being treated with a blood pressure-lowering medicine containing aliskiren;
• if the patient has severe liver disease or a condition called hepatic encephalopathy (a disease damaging the brain);
• if the patient has severe kidney disease causing reduced blood supply to the kidneys (renal artery stenosis);
• if the patient is undergoing dialysis or blood filtration by another method. Depending on the equipment used, Noliprel may not be suitable for the patient;
• if the patient has low potassium levels in the blood;
• if the patient has untreated, decompensated heart failure (severe fluid retention, breathing difficulties);
• if the patient is more than 3 months pregnant (it is also advisable to avoid using Noliprel in early pregnancy – see "Pregnancy");
• if the patient has taken or is currently taking a medicine containing sacubitril and valsartan, used to treat heart failure, because the risk of angioedema (rapid swelling of tissues under the skin in the throat area) increases (see "Warnings and precautions" and "Noliprel with other medicines").

Warnings and precautions
Before starting Noliprel, discuss with your doctor or pharmacist:

• if the patient has aortic valve stenosis (narrowing of the main blood vessel carrying blood from the heart), hypertrophic cardiomyopathy (a heart muscle disease), or renal artery stenosis (narrowing of the blood vessel supplying blood to the kidney);
• if the patient has heart failure or any other heart diseases;
• if the patient has kidney diseases or is undergoing dialysis;
• if the patient experiences worsening vision or eye pain. These may be symptoms of fluid accumulation in the choroid layer of the eye (choroidal effusion) or increased eye pressure, which may occur within hours or weeks after taking Noliprel. Untreated symptoms may lead to permanent vision loss. If the patient previously had an allergy to penicillin or sulfonamides, the risk of these disorders is higher;
• if the patient has muscle disorders, including pain, tenderness, weakness, or muscle cramps;
• if the patient has abnormally increased levels of a hormone called aldosterone in the blood (primary hyperaldosteronism);
• if the patient has liver diseases;
• if the patient has collagenosis (a skin disease), such as systemic lupus erythematosus or scleroderma;
• if the patient has atherosclerosis (hardening of the arteries);
• if the patient has hyperparathyroidism (a disorder of parathyroid gland function);
• if the patient has gout;
• if the patient has diabetes;
• if the patient is on a low-salt diet or uses salt substitutes containing potassium;
• if the patient is taking lithium or potassium-sparing medicines (spironolactone, triamterene), or potassium supplements, these should be avoided during treatment with Noliprel (see "Noliprel with other medicines");
• if the patient is elderly;
• if the patient previously experienced photosensitivity reactions;
• if the patient develops a severe allergic reaction with swelling of the face, lips, mouth, tongue, or throat, causing difficulty in swallowing or breathing (angioedema);
• angioedema may occur at any time during treatment. If such symptoms occur, treatment must be stopped immediately and medical advice sought without delay;
• if the patient is taking any of the following medicines used to treat high blood pressure:
• an angiotensin II receptor antagonist (AIIRA), also known as a sartan – for example, valsartan, telmisartan, irbesartan, especially if the patient has kidney disorders related to diabetes;
• aliskiren. The doctor may recommend regular monitoring of kidney function, blood pressure, and blood electrolyte levels (e.g. potassium). See also the section "When not to use Noliprel";
• if the patient is of Black race – in such cases, there may be a higher risk of angioedema and the medicine may be less effective in lowering blood pressure compared to patients of other races;
• if the patient is undergoing dialysis using high-flux membranes;
• if the patient is taking any of the following medicines, which increase the risk of angioedema:
• racecadotril (used to treat diarrhoea);
• sirolimus, everolimus, temsirolimus, and other medicines belonging to the group of drugs called mTOR inhibitors (used to prevent rejection of transplanted organs and in cancer treatment);
• sacubitril (available in a combination medicine containing sacubitril and valsartan), used to treat chronic heart failure;
• linagliptin, saxagliptin, sitagliptin, vildagliptin, and other medicines belonging to the group of drugs called gliptins (used to treat diabetes).

Angioedema
In patients treated with ACE inhibitors, including Noliprel, cases of angioedema (a severe allergic reaction with swelling of the face, lips, tongue, or throat, and difficulty in swallowing or breathing) have been reported. This reaction may occur at any time during treatment. If such symptoms occur, the patient must stop taking Noliprel immediately and contact a doctor without delay. See also section 4.
Inform your doctor if you are pregnant, suspect you may be pregnant, or are planning pregnancy. Use of Noliprel is not recommended during early pregnancy and must not be taken after 3 months of pregnancy, as it may cause serious harm to the unborn child (see "Pregnancy and breastfeeding").
While taking Noliprel, also inform your doctor or healthcare professional:

• if the patient is to undergo anaesthesia and/or surgery;
• if the patient has recently experienced diarrhoea or vomiting, or is dehydrated;
• if dialysis or LDL apheresis (removal of cholesterol from blood using a special device) is planned;
• if desensitisation treatment is planned to reduce allergic reactions to bee or wasp stings;
• if an imaging test requiring an iodine-containing contrast agent (a substance allowing visualisation of organs such as the kidney or stomach in X-ray examinations) is planned;
• if vision disturbances or pain in one or both eyes occur during treatment with Noliprel. These may be symptoms of glaucoma, increased pressure in one or both eyes. The patient should stop taking Noliprel and consult a doctor immediately.

Athletes should be aware that Noliprel contains an active substance (indapamide) that may lead to a positive result in doping tests.
Children and adolescents
Noliprel must not be used in children and adolescents.
Noliprel with other medicines
Inform your doctor or pharmacist about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take.
Avoid using Noliprel with:

• lithium (used to treat mania or depression);
• aliskiren (a medicine used to treat high blood pressure) in patients who do not have diabetes or kidney function disorders;
• potassium-sparing diuretics (e.g. triamterene, amiloride), potassium salts, or other medicines that may increase potassium levels in the body (such as heparin, a medicine used to thin the blood to prevent clotting; trimethoprim and co-trimoxazole, also known as a combination medicine containing trimethoprim and sulfamethoxazole, used to treat bacterial infections);
• estramustine (used to treat cancer);
• other medicines used to treat high blood pressure: ACE inhibitors and angiotensin II receptor antagonists.

The use of other medicines may affect treatment with Noliprel. The doctor may recommend a dose adjustment and/or additional precautions. Inform your doctor if the patient is taking any of the following medicines, as special caution may be required:

• other medicines used to treat high blood pressure, including angiotensin II receptor antagonists (AIIRAs) or aliskiren (see also sections "When not to use Noliprel" and "Warnings and precautions"), or diuretics (medicines increasing urine output by the kidneys);
• potassium-sparing medicines used to treat heart failure: eplerenone and spironolactone at doses from 12.5 mg to 50 mg per day;
• medicines most commonly used to treat diarrhoea (racecadotril) or to prevent rejection of transplanted organs (sirolimus, everolimus, temsirolimus, and other medicines belonging to the group of drugs called mTOR inhibitors). See section "Warnings and precautions".
• a combination medicine containing sacubitril and valsartan (used to treat chronic heart failure). See sections "When not to use Noliprel" and "Warnings and precautions".
• anaesthetics;
• iodine-containing contrast agents;
• antibiotics used to treat bacterial infections (e.g. moxifloxacin, sparfloxacin, erythromycin administered by injection);
• methadone (used to treat addiction);
• procainamide (used to treat heart rhythm disorders);
• allopurinol (used to treat gout);
• antihistamines used to treat allergic reactions such as hay fever (e.g. mizolastine, terfenadine, astemizole);
• corticosteroids used to treat various diseases, including severe asthma and rheumatoid arthritis;
• immunosuppressive medicines used to treat autoimmune diseases or to prevent organ rejection after transplantation (e.g. cyclosporine, tacrolimus);
• halofantrine (used to treat certain types of malaria);
• pentamidine (used to treat pneumonia);
• gold salts administered by injection (used to treat rheumatoid arthritis);
• vinpocetine (used to treat symptomatic cognitive disorders in elderly patients, including memory loss);
• bepridil (used to treat angina pectoris);
• medicines used to treat heart rhythm disorders (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, ibutilide, dofetilide, digitalis preparations, bretylium);
• cisapride, difenamid (used to treat gastrointestinal disorders);
• digoxin or other cardiac glycosides (used in heart diseases);
• baclofen (used to treat muscle stiffness occurring in diseases such as multiple sclerosis);
• medicines used to treat diabetes, such as insulin, metformin, or gliptins;
• calcium, including calcium supplements;
• stimulant laxatives (e.g. senna);
• non-steroidal anti-inflammatory drugs (e.g. ibuprofen) or high doses of salicylates (e.g. acetylsalicylic acid (a substance contained in many medicines used for pain relief, fever reduction, and prevention of blood clotting));
• intravenous amphotericin B (used to treat severe fungal infections);
• medicines used to treat mental disorders such as depression, anxiety, schizophrenia (e.g. tricyclic antidepressants, neuroleptics (such as amisulpride, sulpiride, sultopride, tiapride, haloperidol, droperidol));
• tetracosactide (used to treat Crohn's disease);
• trimethoprim (used to treat infections);
• vasodilating medicines, including nitrates;
• medicines used to treat low blood pressure, shock, or asthma (e.g. ephedrine, noradrenaline, or adrenaline).

Noliprel with food and drink
It is recommended to take Noliprel before meals.
Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to have a child, she should consult a doctor or pharmacist before using this medicine.
Pregnancy
Inform your doctor if you are pregnant, suspect pregnancy, or are planning pregnancy. Usually, the doctor will advise stopping Noliprel before becoming pregnant or as soon as pregnancy is confirmed, and will recommend an alternative medicine. Noliprel is not recommended during early pregnancy and must not be taken after 3 months of pregnancy, as it may cause serious harm to the unborn child.
Breast-feeding
Noliprel is not recommended if the patient is breastfeeding.
Immediately inform your doctor if the patient is breastfeeding or intends to breastfeed.
Contact your doctor immediately.
Driving and using machines
Noliprel usually does not affect the ability to drive or operate machinery. However, some patients may experience dizziness or fatigue due to low blood pressure.
In such cases, the ability to drive or operate machinery may be impaired.
Noliprel contains lactose monohydrate
If the patient has been diagnosed with an intolerance to certain sugars, he or she should consult a doctor before taking this medicine.
Noliprel contains sodium
Noliprel contains less than 1 mmol of sodium (23 mg) per tablet, meaning the medicine is considered "sodium-free".

3. How to use Noliprel

This medicine should always be taken as directed by your doctor or pharmacist.
If in doubt, consult your doctor or pharmacist.
The recommended dose is one tablet once daily. Your doctor may decide to increase the dose to 2
tablets daily or modify the dosage if you have impaired kidney function.
The tablet should preferably be taken in the morning, before a meal. Swallow the tablet whole with a
glass of water.
The break line on the tablet is not intended for splitting the tablet.

Taking more Noliprel than recommended
If you take more tablets than prescribed, contact your doctor immediately or go to the nearest hospital emergency department.
The most common symptom of overdose is low blood pressure.
If significantly low blood pressure occurs (accompanied by nausea, vomiting, cramps, dizziness, drowsiness, disorientation, or changes in urine output), lying down with your legs elevated may help.

Missed dose of Noliprel
It is important to take the medicine every day, as regular use is most effective.
However, if you miss a dose of Noliprel, take the next dose at your usual time.
Do not take a double dose to make up for a missed dose.

Stopping Noliprel treatment
Treatment for high blood pressure is long-term, so you should consult your doctor before stopping this medicine.
If you have any further questions about the use of this medicine, consult your doctor or pharmacist.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everybody will get them.
If any of the following adverse reactions occur in the patient, which may be serious, stop taking this medicine immediately and contact a doctor without delay:

• severe dizziness or fainting due to low blood pressure (common – may occur in less than 1 in 10 patients);
• bronchospasm (feeling of tightness in the chest, wheezing and shortness of breath; uncommon – may occur in less than 1 in 100 patients);
• swelling of the face, lips, mouth, tongue or throat, breathing difficulties (angioedema, see section “Warnings and precautions” in point 2); uncommon – may occur in less than 1 in 100 patients;
• severe skin reactions, including erythema multiforme (skin rash often starting with red, itchy spots on the face, arms or legs) or severe skin rash, urticaria, redness of the entire skin surface, intense itching, blistering, peeling and swelling of the skin, mucosal inflammation (Stevens-Johnson syndrome) or other allergic reactions (very rare – may occur in less than 1 in 10,000 patients);
• cardiovascular disorders (heart rhythm disturbances, angina pectoris (chest pain radiating to the jaw and back, caused by physical exertion), myocardial infarction; very rare – may occur in less than 1 in 10,000 patients);
• weakness of arms or legs, or speech disturbances, which may be signs of stroke (very rare – may occur in less than 1 in 10,000 patients);
• pancreatitis, which may cause severe upper abdominal pain radiating to the back and severe malaise (very rare – may occur in less than 1 in 10,000 patients);
• yellowing of the skin or eyes (jaundice), which may be a sign of liver inflammation (very rare – may occur in less than 1 in 10,000 patients);
• life-threatening heart rhythm disturbances (frequency unknown);
• brain disease caused by liver disease (hepatic encephalopathy; frequency unknown);
• muscle weakness, cramps, tenderness or muscle pain, particularly when the patient also feels unwell or has a high temperature, which may be due to abnormal muscle breakdown (frequency unknown).

Adverse reactions, grouped by decreasing frequency of occurrence, may include:

• common (may occur in less than 1 in 10 patients): low blood potassium levels, skin reactions in patients with a tendency to allergic and asthmatic reactions, headache, central origin dizziness, labyrinthine origin dizziness, prickling and tingling sensations, visual disturbances, tinnitus (sensation of hearing sounds), cough, shortness of breath, gastrointestinal disturbances (nausea, vomiting, abdominal pain, taste disturbances, dyspepsia or digestive disorders, diarrhoea, constipation), allergic reactions (such as skin rashes, itching), muscle cramps, feeling of fatigue.

• uncommon (may occur in less than 1 in 100 patients): mood swings, depression, sleep disturbances, urticaria, purpura (small red spots on the skin), blister clusters, kidney disorders, impotence (inability to achieve or maintain erection), excessive sweating, increased eosinophil count (a type of white blood cells), changes in laboratory test results: high blood potassium levels, which may resolve after discontinuation of treatment, low blood sodium levels, which may cause dehydration and low blood pressure, drowsiness, fainting, palpitations (awareness of heartbeat), tachycardia (fast heart rate), hypoglycaemia (very low blood sugar levels) in diabetic patients, vasculitis (inflammation of blood vessels), dryness of the oral mucosa, photosensitivity reactions (increased skin sensitivity to sunlight), joint pain, muscle pain, chest pain, malaise, peripheral oedema, fever, increased blood urea levels, increased blood creatinine levels, falls.

• rare (may occur in less than 1 in 1,000 patients): worsening of psoriasis, changes in laboratory test results: low blood chloride levels, low blood magnesium levels, increased liver enzyme activity, high serum bilirubin levels; fatigue, sudden flushing of the face and neck, reduced or absent urine output, acute kidney failure. Dark-coloured urine, nausea or vomiting, muscle cramps, disorientation and seizures. These may be symptoms of a condition called SIADH (syndrome of inappropriate antidiuretic hormone secretion).

• very rare (may occur in less than 1 in 10,000 patients): disorientation, eosinophilic pneumonia (a rare type of lung inflammation), rhinitis (nasal congestion or runny nose), severe kidney disorders, blood parameter changes such as decreased white and red blood cell counts, decreased haemoglobin concentration, decreased platelet count, high blood calcium levels, liver function disorders.

• frequency not known (cannot be estimated from available data): abnormal heart function detected on ECG examination, changes in laboratory test results: low potassium levels, high uric acid levels and high blood sugar levels, myopia, blurred vision, visual disturbances, worsening of vision or eye pain due to high pressure (possible symptoms of fluid accumulation in the choroid layer of the eye (choroidal effusion) or acute angle-closure glaucoma), cyanosis, numbness and pain in fingers or toes (Raynaud's phenomenon). If the patient has systemic lupus erythematosus (a type of collagenosis), disease symptoms may worsen.

Blood, kidney, liver or pancreas disorders and changes in laboratory test results (blood tests) may occur.
Your doctor may recommend blood tests to monitor your health.
If any of these symptoms occur, contact your doctor as soon as possible.
Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, inform your doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting adverse reactions helps provide more information on the safety of this medicine.

5. How to store the medicine Noliprel

Keep the medicine out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the stated month.
Store the container tightly closed to protect from moisture.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. Such measures will help protect the environment.

6. Contents of the packaging and other information

Active substances in Noliprel

• The active substances in this medicine are perindopril and indapamide. One coated tablet contains 2.5 mg of perindopril arginine (equivalent to 1.6975 mg of perindopril) and 0.625 mg of indapamide.
• Other components of the tablet core: monohydrate lactose, magnesium stearate, maltodextrin, colloidal anhydrous silica, sodium carboxymethyl starch (type A); components of the coating: glycerol, hypromellose, macrogol 6000, magnesium stearate, titanium dioxide (E 171).

What Noliprel looks like and contents of the packaging
Noliprel is a white, elongated coated tablet with an embossed line on both sides. Each coated tablet contains 2.5 mg of perindopril arginine and 0.625 mg of indapamide.
The tablets are available in packages containing 30, 60, and 90 tablets.
For more detailed information, please contact the marketing authorisation holder or the parallel importer.
Marketing authorisation holder in Latvia, country of export:
Les Laboratoires Servier
50, rue Carnot
92284 Suresnes cedex, France
Manufacturer:
ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.
ul. Annopol 6B
03-236 Warszawa, Poland
Les Laboratoires Servier Industrie
905 route de Saran
45520 Gidy, France
Servier (Ireland) Industries Ltd
Gorey Road
Arklow - Co. Wicklow, Ireland
Parallel importer:
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warszawa, Poland
Repackaged at:
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warszawa, Poland
Marketing authorisation number in Latvia, country of export: 07-0015
Parallel import authorisation number: 389/24
This medicinal product is authorised for sale in the European Economic Area under the following names:
Austria PRETERAX-ARGININ
Belgium PRETERAX 2.5 mg/0.625 mg
Cyprus COVERSYL PLUS ARGININE 2.5 mg/0.625 mg
Estonia NOLIPREL ARGININE
Finland PRETERAX NOVUM
France PRETERAX 2.5mg/0.625mg
Germany PRETERAX N 2.5 mg/ 0.625 mg Filmtabletten
Greece PRETERAX 2.5 mg/0.625 mg
Ireland COVERSYL ARGININE PLUS 2.5mg/0.625mg
Italy PRETERAX 2.5 mg/0.625 mg
Latvia NOLIPREL ARGININE 2.5mg/0.625mg coated tablets
Lithuania NOLIPREL 2.5 mg/0.625 mg tabletès
Luxembourg PRETERAX 2.5 mg/0.625 mg
Poland NOLIPREL
Portugal PRETERAX 2.5 mg/0.625 mg
Romania NOLIPREL ARG 2.5 mg/ 0.625 mg
Slovakia NOLIPREL A
Slovenia BIONOLIPREL 2.5mg/0.625mg filmsko obložene tablete
Translation of the symbols for days of the week appearing on the immediate packaging:
P – Monday, O – Tuesday, T – Wednesday, C – Thursday, Pk – Friday, S – Saturday, Sv – Sunday.